Menu

Notable Science Quotes

Roger Tsien R.I.P., predatory publishing, and diversity in science

Oct 1, 2016
The Scientist Staff

IN LOVING COLOR: An agar plate of fluorescent bacteria colonies created in Roger Tsien’s lab.
TSIEN LAB, UNIVERSITY OF CALIFORNIA, SAN DIEGO

I’ve always been attracted to colors. Color helps make the work more interesting and endurable. It helps when things aren’t going well. If I had been born colorblind, I probably never would have gone into this.

—Late biologist Roger Tsien of the University of California, San Diego, reflecting on his 2008 Nobel Prize for Chemistry, which he shared for his role in the development of green florescent protein (San Diego Union-Tribune, October 8, 2008)

 

Rarely are the smartest people the most creative too, but Roger was both.

—Nobel Laureate K. Barry Sharpless of the Scripps Research Institute in La Jolla, California, remembering biologist and fellow Nobelist Roger Tsien, who died in late August at the age of 64 (Los Angeles Times, August 31)

 

We take no sides between the traditional subscription model and the open-access model. We believe both of them can be done in a fair, open, clear, and lawful way. What we have a problem with here is people who are trying to benefit from the open-access model to scam people.

Ioana Rusu, an attorney with the US Federal Trade Commission, on the legal complaint the FTC filed with alleged predatory publisher OMICS Group (Inside Higher Ed, August 29)

 

Brain size has increased about 350 percent over human evolution, but we found that blood flow to the brain increased an amazing 600 percent. We believe this is possibly related to the brain’s need to satisfy increasingly energetic connections between nerve cells that allowed the evolution of complex thinking and learning.

—Australian biologist Roger Seymour of the University of Adelaide, in a statement on his team’s recent study published in Royal Society Open Science (August 31)

 

If you’re looking for meaningful outcomes at the end of five years, then you might as well pull the plug now, because [NRMN] is going to fail. . . . Many of us are concerned that if NIH officials don’t see results immediately, they will say, “Too bad, we tried. But that’s the best we can do.”

Donald Wilson, cofounder of the Association for Academic Minority Physicians, commenting on the National Institutes of Health’s new five-year, $22 million National Research Mentoring Network (NRMN), designed to increase diversity in the biomedical workforce (Science, September 2)

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.